Kailera nets $600M more to advance Zepbound-like obesity drug

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.

By Jonathan Gardner • Oct. 14, 2025

BioCryst goes ‘all in’ on rare swelling disease with Astria deal

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema that complements its daily pill.

By Delilah Alvarado • Oct. 14, 2025

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

A young biotech nets $70M for a new type of allergy drug

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company says could lead to faster and more complete disease control.

By Gwendolyn Wu • Oct. 13, 2025

Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a dozen children with a rare, genetic form of deafness.

By Jacob Bell • Oct. 12, 2025

AstraZeneca ups investment in Virginia; Moderna vets launch VC fund

The British pharma is adding $500 million, and ADC production capabilities, to a planned Virginia facility. Elsewhere, Ferring announced layoffs and Sanofi touted a radiopharmaceutical drug.

By BioPharma Dive staff • Oct. 10, 2025

Evommune files for IPO to advance immune drug work

The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for chronic skin hives.

By Gwendolyn Wu • Oct. 10, 2025

Regeneron, needing a turnaround, gains new use for cancer drug

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the “broad-reaching implications” for Regeneron's Eylea franchise investors had hoped.

By Kristin Jensen • Oct. 9, 2025

Arthrosi snags $153M in pursuit of a new gout drug

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve upon existing therapies. 

By Ben Fidler • Oct. 8, 2025

Venture firms pour $101M into a biotech using the brain to fix the immune system

Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by targeting a special kind of nerve cell.

By Jacob Bell • Oct. 8, 2025

Zenas looks to China to stock pipeline with 3 more immune drugs

A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple sclerosis and two other immune medicines in earlier development.

By Kristin Jensen • Oct. 8, 2025

MapLight uses workaround to tee up IPO during government shutdown

The company set terms for an offering with the help of a little-used section of the Securities Act that would enable its IPO to price automatically in 20 days.

By Gwendolyn Wu • Oct. 7, 2025

Skye shares crash as obesity drug falls short in key study

The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to boost the effects of incretin therapies like Wegovy.

By Ben Fidler • Oct. 6, 2025

Gilead delays arrival of Biktarvy copycats; CDC updates vaccine schedule

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug acquisition paid more dividends and a Vertex veteran became Stoke’s full-time CEO.

By BioPharma Dive staff • Oct. 6, 2025

Chiesi buys into Arbor gene editing drug for rare kidney disease

The Italian drugmaker will pay as much as $115 million in upfront and near-term payments in a deal that gives it rights to a treatment in early-stage testing for primary hyperoxaluria type 1.

By Gwendolyn Wu • Oct. 6, 2025

Immune reset: How T cell engagers can change the autoimmune treatment landscape

T cell engagers could redefine autoimmune care around lasting remission and patient experience.

By Jeffrey Jones, Chief Medical Officer, Cullinan Therapeutics • Oct. 6, 2025

FDA clears generic abortion pill; CMS punts ‘combo drug’ guidance

The decision to clear another mifepristone generic sparked political backlash. Elsewhere, investors will pump up to $175 million into Ovid after the company reported early, but encouraging, data for a potential epilepsy drug.

By BioPharma Dive staff • Oct. 3, 2025

Cartography secures $67M in pursuit of ‘differentiated’ cancer drugs

The company is working on T cell engagers and other multifunctional antibodies, led by a prospect it believes might be helpful treating the vast majority of colorectal cancer cases.

By Gwendolyn Wu • Oct. 2, 2025

The top biopharma conferences in 2026

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.

By Ben Fidler • Oct. 1, 2025

A new biotech aims to get RNA drugs into the brain

Dublin-based Aerska launched on Wednesday with $21 million in seed funding and a technology designed to shuttle RNA interference medicines past the blood-brain barrier.

By Jacob Bell • Oct. 1, 2025

As shutdown begins, FDA to stop accepting new drug submissions

The funding lapse triggered by the U.S. government shutdown is the latest test for an agency that’s already dealt with significant layoffs and leadership upheaval this year.

By Kristin Jensen • Oct. 1, 2025

FDA official’s comments spark Aurinia sell-off; Halozyme buys a biotech

George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new Novartis drug and two biotechs cut staff.  

By BioPharma Dive staff • Oct. 1, 2025

Metsera strengthens case for Pfizer buyout with latest study data

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.

By Jonathan Gardner • Sept. 30, 2025

Crystalys debuts with $205M and plans for a better gout drug

The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see as a superior version of the now-withdrawn gout medication Zurampic.

By Gwendolyn Wu • Sept. 30, 2025

Star raises another $125M for its blood disease drug

Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to standard therapies for Von Willebrand disease.

By Gwendolyn Wu • Sept. 30, 2025

Genmab to acquire closely watched cancer drug in $8B Merus buyout

The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when added to Merck’s widely used immunotherapy Keytruda.

By Delilah Alvarado • Sept. 29, 2025